| Literature DB >> 29724878 |
Chiara Verdelli1, Irene Forno2,3, Annamaria Morotti2,3, Pasquale Creo4, Vito Guarnieri5, Alfredo Scillitani6, Filomena Cetani7, Leonardo Vicentini8, Gianni Balza9, Edoardo Beretta10, Stefano Ferrero3,11, Valentina Vaira12,3, Sabrina Corbetta13.
Abstract
Parathyroid tumors deregulate microRNAs belonging to the two clusters on the chromosome 19, the C19MC and miR-371-373 clusters. Here, we report that the embryonic miR-372 is aberrantly expressed in half of parathyroid adenomas (PAds) in most of atypical adenomas and carcinomas (n = 15). Through in situ hybridization, we identified that miR-372-positive parathyroid tumor cells were scattered throughout the tumor parenchyma. In PAd-derived cells, ectopic miR-372 inhibited the expression of its targets CDKN1A/p21 and LATS2 at both mRNA and protein levels. Although the viability of parathyroid cells was not affected by miR-372 overexpression, the miRNA blunted camptothecin-induced apoptosis in primary PAd-derived cultures. miR-372 overexpression in parathyroid tumor cells increased parathormone (PTH) mRNA levels, and it positively correlated in vivo with circulating PTH levels. Conversely, the parathyroid-specific genes TBX1 and GCM2 were not affected by miR-372 mimic transfection. Finally, miR-372 dampened the Wnt pathway in parathyroid tumor cells through DKK1 upregulation. In conclusion, miR-372 is a novel mechanism exploited by a subset of parathyroid tumor cells to partially decrease sensitivity to apoptosis, to increase PTH synthesis and to deregulate Wnt signaling.Entities:
Keywords: LATS2; Wnt/beta-catenin; hyperparathyroidism; miR-372; microRNA; p21; parathyroid tumors
Mesh:
Substances:
Year: 2018 PMID: 29724878 DOI: 10.1530/ERC-17-0204
Source DB: PubMed Journal: Endocr Relat Cancer ISSN: 1351-0088 Impact factor: 5.678